febuxostat has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abedi, SM; Alizadeh-Navaei, R; Davoodi, L; Hosseinimehr, SJ; Khorasani, G; Rouhanizadeh, H; Salehifar, E | 1 |
| Bandyopadhyay, D; Deedwania, P; Fonarow, GC; Ghosh, RK; Gupta, M; Hajra, A; Kaul, S; Klein, A; Lavie, CJ; Mamas, M; Roddy, E | 1 |
1 review(s) available for febuxostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
Topics: Cardiovascular Diseases; Colchicine; COVID-19; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Pandemics | 2021 |
1 trial(s) available for febuxostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.
Topics: Adult; Aged; Ambulatory Care; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Administration Schedule; Febuxostat; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |